Druggability & Clinical Context
Druggability
Low
Score: 0.32
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
1
Known Drugs:
4
Approved:
0
In Clinical Trials:
3
Drug Pipeline (4 compounds)
1 Preclinical
Druggability Rationale: CHMP2B has low druggability (0.30) as a structural ESCRT-III component lacking a well-defined ligand-binding pocket, making direct small-molecule inhibition unfeasible. Current therapeutic strategies circumvent this limitation by targeting upstream regulators (autophagy enhancers, GLP-1 agonists) or modulating CHMP2B expression indirectly via antisense oligonucleotides rather than occupying a conserved binding site.
Mechanism: Therapeutic agents targeting CHMP2B would modulate ESCRT-III complex function to enhance endosomal sorting and autophagy, potentially clearing protein aggregates associated with frontotemporal dementia or compensating for loss-of-function mutations. Strategies include antisense oligonucleotides to modulate protein expression, autophagy enhancers to promote cellular clearance pathways, or small molecules that stabilize ESCRT-III complex assembly and function.
Drug Pipeline (4 compounds)
1 Preclinical
Known Drugs:ISIS 420915 (Antisense against Tau) (phase2) — Frontotemporal Dementia associated with Progranulin mutations
BIIB078 (phase1) — C9ORF72-related frontotemporal dementia and ALS
GLP-1 Receptor Agonists (Liraglutide derivatives) (phase2) — Neuroinflammation in Frontotemporal Dementia
Autophagy modulators (Experimental compounds) (preclinical) — ESCRT-III pathway dysfunction and neurodegeneration
Structural Data:PDB (1) ✓AlphaFold ✓Cryo-EM —
Selectivity & Safety Considerations
CHMP2B selectivity challenges stem from high homology with other ESCRT-III family members (CHMP2A, CHMP3, CHMP4); antisense and autophagy modulator approaches offer better selectivity through sequence-specific targeting. Off-target effects on general autophagy or endosomal sorting pathways represent the primary risk for systemic modulators.